Poster

Development Of Binding Assays To Measure Interactions Between Fc Regions Of Therapeutic Monoclonal Antibodies And Fc Receptors Using Surface Plasmon Resonance

Source: MilliporeSigma

By D. Raghu, Y.T. Hsu, L. Kelly, P. Hamill, and M. McKee

The therapeutic monoclonal antibody (mAb) market continues to grow as it allows for treaments with higher specificity through direct antigenic targeting. Complex characterization of mAbs is challenging due to their ability to bind to a variety of Fc receptors via their Fc domains, in addition to specific antigen binding via their Fab domain. mAb interactions with Fc receptors result in diverse biological functions associated with each domain. The Fc domain of mAbs interacts with Fc receptors with varying affinities, which can influence biological processes such as Complement Dependent Cytotoxicity (CDC), Antibody-Dependent Cellular Cytotoxicity (ADCC), Antibody Dependent Cellular Phagocytosis (ADCP) and/or serum half-life.

An important characteristic of an antibody is its Fc effector function, and antibodies are now being engineered for optimal binding to Fc receptors expressed on effector cells. Hence it is crucial to evaluate the binding interaction of mAbs with Fc receptors in the early phase of drug development to understand the potential biological activity of the product in vivo.

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: